{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:47:12Z","timestamp":1761101232528,"version":"build-2065373602"},"reference-count":25,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,4,10]],"date-time":"2015-04-10T00:00:00Z","timestamp":1428624000000},"content-version":"vor","delay-in-days":433,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute (NCI)","doi-asserted-by":"crossref","award":["N00014-12-1-0142"],"award-info":[{"award-number":["N00014-12-1-0142"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung and Blood Institute (NHLBI)","doi-asserted-by":"crossref","award":["N00014-13-1-0039"],"award-info":[{"award-number":["N00014-13-1-0039"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000006","name":"Office of Naval Research","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000006","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100010299","name":"Allos Therapeutics, Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100010299","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100002429","name":"Amgen, Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Anonymous donation to the Medical College of Wisconsin"},{"DOI":"10.13039\/100006413","name":"Ariad","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006413","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100001738","name":"Be the Match Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001738","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Blue Cross and Blue Shield Association; Celgene Corporation"},{"name":"Fresenius-Biotech North America, Inc."},{"name":"Gamida Cell Teva Joint Venture Ltd."},{"DOI":"10.13039\/100004328","name":"Genentech, Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Gentium SpA"},{"name":"Genzyme Corporation"},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Histogenetics, Inc."},{"DOI":"10.13039\/501100004072","name":"Kiadis Pharma","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004072","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100005189","name":"The Leukemia & Lymphoma Society","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"crossref"}]},{"name":"The Medical College of Wisconsin"},{"DOI":"10.13039\/100004334","name":"Merck & Co, Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Millennium: The Takeda Oncology Co."},{"name":"Milliman USA, Inc."},{"name":"Miltenyi Biotec, Inc."},{"name":"National Marrow Donor Program"},{"DOI":"10.13039\/100007072","name":"Onyx Pharmaceuticals","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007072","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Optum Healthcare Solutions, Inc."},{"DOI":"10.13039\/100007075","name":"Osiris Therapeutics, Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007075","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100009155","name":"Otsuka America Pharmaceutical, Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009155","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Remedy Informatics"},{"DOI":"10.13039\/100004339","name":"Sanofi US","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100010293","name":"Seattle Genetics","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100010293","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100009996","name":"Sigma-Tau Pharmaceuticals","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009996","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Soligenix, Inc."},{"DOI":"10.13039\/100008761","name":"StemCyte, A Global Cord Blood Therapeutics Co","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008761","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Stemsoft Software, Inc."},{"DOI":"10.13039\/501100012112","name":"Swedish Orphan Biovitrum","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012112","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100007127","name":"Tarix Pharmaceuticals","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007127","id-type":"DOI","asserted-by":"crossref"}]},{"name":"TerumoBCT"},{"name":"Teva Neuroscience, Inc."},{"DOI":"10.13039\/100007163","name":"THERAKOS, Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007163","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004382","name":"Wellpoint, Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004382","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.bbmt.2013.10.023","type":"journal-article","created":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T08:04:49Z","timestamp":1383293089000},"page":"202-208","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Effect of Postremission Therapy before Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia in First Complete Remission"],"prefix":"10.1016","volume":"20","author":[{"given":"Erica D.","family":"Warlick","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristjan","family":"Paulson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruta","family":"Brazauskas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaobo","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan M.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce M.","family":"Camitta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biju","family":"George","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bipin N.","family":"Savani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Celalettin","family":"Ustun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David I.","family":"Marks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edmund K.","family":"Waller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Baron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9sar O.","family":"Freytes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00e9rard","family":"Socie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gorgun","family":"Akpek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harry C.","family":"Schouten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hillard M.","family":"Lazarus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edwin M.","family":"Horwitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Koreth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Yves","family":"Cahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Bornhauser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Seftel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitchell S.","family":"Cairo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary J.","family":"Laughlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitchell","family":"Sabloff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olle","family":"Ringd\u00e9n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert Peter","family":"Gale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rammurti T.","family":"Kamble","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravi","family":"Vij","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Usama","family":"Gergis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vikram","family":"Mathews","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wael","family":"Saber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Bin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane L.","family":"Liesveld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corey S.","family":"Cutler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armin","family":"Ghobadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geoffrey L.","family":"Uy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Eapen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel J.","family":"Weisdorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark R.","family":"Litzow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2013.10.023_bib1","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJM199410063311402","article-title":"Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and leukemia group B","volume":"331","author":"Mayer","year":"1994","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2013.10.023_bib2","doi-asserted-by":"crossref","first-page":"4075","DOI":"10.1182\/blood.V96.13.4075","article-title":"Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: A Southwest Oncology Group\/Eastern Cooperative Oncology Group study","volume":"96","author":"Slovak","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.10.023_bib3","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1182\/blood-2009-11-254441","article-title":"Refinement of cytogenetic classification in acute myeloid leukemia: Determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the united kingdom medical research council trials","volume":"116","author":"Grimwade","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.10.023_bib4","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1001\/jama.2009.813","article-title":"Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: Systematic review and meta-analysis of prospective clinical trials","volume":"301","author":"Koreth","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.bbmt.2013.10.023_bib5","first-page":"1254","article-title":"Effect of postremission chemotherapy before human leukocyte antigen-identical sibling transplantation for acute myelogenous leukemia in first complete remission","volume":"96","author":"Tallman","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.10.023_bib6","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1046\/j.1365-2141.2000.02178.x","article-title":"No impact of high-dose cytarabine on the outcome of patients transplanted for acute myeloblastic leukaemia in first remission. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)","volume":"110","author":"Cahn","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2013.10.023_bib7","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1182\/blood-2004-05-1947","article-title":"Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age","volume":"105","author":"Alyea","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.10.023_bib8","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.bbmt.2006.06.003","article-title":"Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome","volume":"12","author":"Alyea","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.10.023_bib9","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1182\/blood-2005-11-4503","article-title":"Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes","volume":"108","author":"Martino","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.10.023_bib10","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/sj.bmt.1705879","article-title":"Comparable non-relapse mortality and survival after HLA-identical sibling blood stem cell transplantation with reduced or conventional-intensity preparative regimens for high-risk myelodysplasia or acute myeloid leukemia in first remission","volume":"41","author":"Martino","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.10.023_bib11","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/bmt.2011.69","article-title":"Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS","volume":"47","author":"Luger","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.10.023_bib12","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/S1470-2045(12)70349-2","article-title":"Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: A prospective, open-label randomised phase 3 trial","volume":"13","author":"Bornhauser","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bbmt.2013.10.023_bib13","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/joim.12056","article-title":"A\u00a0prospective randomized toxicity study to compare reduced-intensity and myeloablative conditioning in patients with myeloid leukemia undergoing allogeneic haematopoietic stem cell transplantation","volume":"274","author":"Ringden","year":"2013","journal-title":"J\u00a0Intern Med"},{"key":"10.1016\/j.bbmt.2013.10.023_bib14","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.leukres.2010.12.013","article-title":"Pre-transplant consolidation chemotherapy may not improve outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for acute myeloid leukemia in first complete remission","volume":"35","author":"McCormack","year":"2011","journal-title":"Leuk Res"},{"key":"10.1016\/j.bbmt.2013.10.023_bib15","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.bbmt.2008.04.003","article-title":"Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: Revised definitions to predict survival","volume":"14","author":"Weisdorf","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.10.023_bib16","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.bbmt.2008.12.497","article-title":"Reduced-intensity conditioning regimen workshop: Defining the dose spectrum. Report of a workshop convened by the Center for International Blood and Marrow Transplant Research","volume":"15","author":"Giralt","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.10.023_bib17","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regimens: Working definitions","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.10.023_bib18","first-page":"18","article-title":"Harnessing graft-versus-malignancy: Non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy","volume":"111","author":"Champlin","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2013.10.023_bib19","first-page":"825","article-title":"1994 consensus conference on acute GVHD grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.10.023_bib20","doi-asserted-by":"crossref","first-page":"4242","DOI":"10.1182\/blood-2011-03-344390","article-title":"Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH consensus criteria","volume":"118","author":"Arai","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.10.023_bib21","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J\u00a0Am Stat Assoc"},{"key":"10.1016\/j.bbmt.2013.10.023_bib22","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1200\/JCO.2005.06.090","article-title":"Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: A cancer and leukemia group B study","volume":"23","author":"Farag","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2013.10.023_bib23","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2012-07-444851","article-title":"Sense and nonsense of high-dose cytarabine for acute myeloid leukemia","volume":"121","author":"Lowenberg","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.10.023_bib24","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/bmt.2012.139","article-title":"Prognostic and therapeutic implications of minimal residual disease at the time of transplantation in acute leukemia","volume":"48","author":"Buckley","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.10.023_bib25","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1200\/JCO.2010.31.8121","article-title":"Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia","volume":"29","author":"Walter","year":"2011","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879113005004?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879113005004?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:46:44Z","timestamp":1761058004000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879113005004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["S1083879113005004"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2013.10.023","relation":{},"ISSN":["1083-8791"],"issn-type":[{"type":"print","value":"1083-8791"}],"subject":[],"published":{"date-parts":[[2014,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of Postremission Therapy before Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia in First Complete Remission","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2013.10.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}